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Low protein diet in uremia: Effects on glucose metabolism and energy
production rate. Low-protein diets (LPD) increase insulin-mediated glu-
cose disposal in chronic renal failure (CRF), but the fate of the better
utilized glucose and the effect on energy production rate are unknown.
Using a two-step (1 and 5 mU kg1 min ')euglycemic hyperinsulinemic
clamp combined with indirect calorimetry, we studied the effects of a LPD
(0.3 g kg1 day1, supplemented with essential amino acids and
ketoanalogs) in six patients suffering from chronic renal failure. After
three months of diet, no significant change was observed concerning
glomerular filtration rate, body wt, or arterial pH. In the postabsorptive
state, plasma glucose and insulin levels were significantly lower, and
energy production rose from 15.72 0.48 to 17.16 0.67 Cal - kg
min1 (P < 0.05). Insulin-stimulated glucose oxidation (2.36 0.29 vs.
3.37 0.35 mg kg min; P < 0.05 at first clamp step) and
nonoxidative disposal (P < 0.05 at both clamp steps) increased after LPD.
This confirms that LPD ameliorates insulin sensitivity in CRF, even for
low plasma insulin concentrations. Since energy production rate is in-
creased by LPD, the caloric intake should be increased when protein
intake is restricted.
Insulin resistance and hyperinsulinemia are well-known fea-
tures of chronic renal failure (CRF) [1, 2], and may play a role in
the increased cardiovascular morbidity in chronically uremic
patients. We previously showed that a low-protein diet (LPD)
improved insulin sensitivity [3J and increased insulin metabolic
clearance rate [4] in such patients.
The glucose that is more efficiently taken up by tissues during a
hyperinsulinemic euglycemic clamp is essentially removed by
muscle, and can have two metabolic fates: oxidative, or nonoxi-
dative disposal (mainly glycogen synthesis). We do not yet know
which of these two metabolic pathways is more responsive to
insulin in patients on LPD.
An improvement in glucose storage, which is preferentially
affected by insulin resistance in CRF [5], is the most likely
explanation of the beneficial effect of LPD on glucose metabolism
in CRF. However, Eidemak et al have demonstrated a positive
correlation between insulin sensitivity and aerobic work capacity
in CRF [61, suggesting that the oxidative metabolism of glucose
might also be important. Moreover, the mechanism of the im-
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provement by LPD is not necessarily related to the pathophysiol-
ogy of the defect in CRF, as beneficial effects of LPD on glucose
metabolism have been reported in nonuremic diabetic patients
[71. Finally, as recently underlined by H. Yki-Jflrvinen, it is much
more unlikely to detect a defect in glucose oxidation than storage,
because a notable part is not insulin dependent (oxidation by
brain, and heart) and oxidation is quantitatively less important
than storage at high insulin concentrations [8]. In contrast, at a
moderate (physiological) insulin level, both metabolic pathways
contribute to the utilization of glucose in almost similar propor-
tions. Therefore, an LPD-induced improvement in insulin sensi-
tivity of oxidative glucose metabolism should not be excluded, and
use of a moderate insulin infusion rate should permit its detection.
The major potential adverse effect of LPD is malnutrition,
which has been attributed in uremic patients to several factors
such as uremia itself, metabolic acidosis, a decrease in energy and
protein intake, hypercatabolic status, and secondary hyperpara-
thyroidism [9]. The protein-sparing effect of a sufficient caloric
intake is well established [101, but, to our knowledge, the possi-
bility that protein restriction may in itself modify energy produc-
tion rate in uremic patients has not been examined.
Using the glucose-clamp technique with moderate (1 mU- kg1
min1) and high (5 mU kg1 - min') insulin infusion rates in
combination with indirect calorimetry, we measured insulin-
stimulated glucose oxidation, nonoxidative glucose disposal and
energy production rate in six patients with advanced renal failure
before and after three months of LPD.
Methods
Patients
Six patients (5 men, 1 postmenopausal woman) were studied.
Their mean age was 46.5 5.7 years. Mean body wt was 73.5
3.8 kg and height 174 3 cm. The underlying renal diseases were
as follows: chronic glomerulonephritis (N = 2), interstitial ne-
phropathy (N = 2), polycystic kidney disease (N = 1), and
sequellae of Moschowitz's syndrome (N = I). All were nondia-
lyzed patients with advanced renal failure. Serum creatinine was
455 43 jimol - liter' and glomerular filtration rate (GFR),
assessed by urinary clearance of 51Cr-EDTA as previously de-
scribed [111, was 13.6 3.1 ml - min'. They presented no other
major organ system disease, and none was taking any medication
known to interfere with carbohydrate metabolism. Exclusion
criteria were hepatic failure, diabetes mellitus, a family history of
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diabetes mellitus, and metabolic acidosis (because its correction
might interfere with interpretation of indirect calorimetry results
[121). Nutritional status was assessed by body wt, mid-arm circum-
ference, triceps skinfold thickness, serum protein and albumin
levels. Plasma sodium, chloride and potassium concentrations
were within the normal range. The experimental protocol was
approved by the ethics committee of our institution. All patients
gave informed consent to the procedures of the study.
Low-protein diet
Patients were first studied while on their usual unrestricted diet,
providing in every case at least 0.8 g protein and 10 to 13 mg
inorganic phosphorus per kg body wt daily. Patients were pre-
scribed a LPD providing, per kg body wt, 0.3 g protein of
vegetable origin and 5 to 7 mg inorganic phosphorus. The energy
supplied (35 kCal kg1 day1) was furnished mainly by
carbohydrates (67%), with lipids accounting for 30% of the energy
intake. Monthly adjustments in the caloric intake based on dietary
interviews were made for weight maintenance. In patients with
heavy proteinuria, each gram of urinary protein loss was replaced
by an additional 1.25 g protein of high biological value of animal
origin. The LPD was supplemented with essential amino acids and
ketoanalogs (to minimize nitrogen intake) in tablet form (Ce-
tolog; Clintec Laboratory, Amilly, France; the composition of
tablets is provided in the Appendix), one tablet per 5 kg body wt
given daily in divided doses with meals, calcium carbonate at a
dose of 1 to 2 g in order to maintain normal serum calcium
concentration, iron and a multivitamin preparation providing 25
jtg (1000 IU) ergocalciferol per day. Compliance was verified
monthly by dietary interview and by measurements of urinary urea
and phosphorus excretion. Antihypertensive medication was not
modified during the study (no subject was on betablockers or
angiotensin converting enzyme inhibitors).
Materials
Common human insulin was obtained from Novo Nordisk
(Copenhagen, Denmark). Respiratory exchange measurements
were performed with a computerized flow-through canopy gas
analyzer system (Deltatrac metabolic monitor; Datex, Helsinki,
Finland).
Study design
All subjects were studied twice, before and after three months
of LPD (Fig. 1). Studies were performed in the postabsorptive
(PA) state after overnight fasting. Tests began at 9:30 a.m. with a
30-minute basal period to measure postabsorptive substrate oxi-
dation rates. Then a two-step hyperinsulinemic-euglycemic clamp
was performed, each step lasting 120 minutes, with two successive
insulin infusion rate determinations (1 and 5 mU kg1 min1).
Study procedures
Patients were admitted in the metabolic ward the evening
before the test, and allowed to rest in the supine position.
Intravenous catheters were inserted into veins of one forearm for
different infusions. To obtain arterialized blood samples, another
catheter was inserted in a retrograde manner into a vein of the
contralateral hand kept at 55°C in an electric blanket. Initial blood
samples were obtained, and then respiratory exchange measure-
ments began. At 30 minutes, the clamp was started and primed-
continuous insulin infusion began. Insulin was dissolved in 48 ml
of saline (154 mmol liter 1) mixed with 2 ml of blood taken from
the patient. Each insulin infusion was primed according to Rizza,
Mandarino and Gerich [13], and the continuous infusion rates
were 1.0 and 5.0 mU kg' min1 for 120 minutes each,
delivered by an electric syringe (Havard Apparatus, Les Ulis,
France). Euglycemia was maintained according to the clamp
technique, automatically by an artificial pancreas (Biostator
GCIIS; Laboratoire Miles, Epernon, France) working in a 9:1
mode (no human intervention) as previously described [31. Exog-
enous glucose infusion rates necessary to maintain euglycemia (M
value) were measured during the last 30 minutes of each step of
the clamp. During the basal period and the last 30 minutes of the
two clamp steps, arterialized blood samples were withdrawn every
10 minutes and a plastic ventilation hood was placed over the
head of the subject and made airtight around the neck, allowing
measurement of respiratory exchanges with the Deltatrac Meta-
bolic Monitor. Urine samples were collected at the beginning and
end of each test.
Analytical procedures
Plasma glucose concentration was determined by the glucose
oxidase method [14]. Urinary N was defined as the sum of urinary
urea (mmol . min1), creatinine (mmol min') and uric acid
(mmol min) N, determined using routine, semiautomated
methods:
UN (minol niin1) = (2 x Uurea) + (3 >< Uc) + (4 x UUricaQd)
As reported by Thorburn et al [15], this gives results comparable
to the Kjeldahl method, with comparable trends during euglyce-
mic hyperinsulinemic clamp studies. We did not measure global
urinary N by a classical Kjeldhal method to avoid the inclusion of
N from proteinuria that was present in some of our patients.As
proposed by Thorburn et al, we calculated the corrected values for
urinary N during the clamp, to take into account the insulin-
induced changes in urea clearance rate [15]. Serum total calcium,
phosphorus, uric acid, urea and bicarbonates, arterial pH, hemo-
globin and hematocrit were measured by routine, semiautomated
methods. Plasma insulin and intact PTH were determined by
radioimmunoassay (Pharmacia kit for insulin and Sorin kit for
PTH).
Calculations
Protein oxidation (POx) was estimated as [16]:
POx(mg kgmin1) = 6.25 X U(mgkg1 .min1)
I I I I
Insulin, mu/kg/mm
1
Indirect calorimetry
Sampling Blood $+
Urine $
Fig. 1. Study design.
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Total glucose and lipid oxidation rates were calculated from gas
exchange measurements during the postabsorptive period and last
30 minutes of each clamp step using the equations proposed by
Ferrannini [16]. During the clamp, total suppression of endoge-
nous glucose production was assumed and glucose utilization was
considered as equal to exogenous glucose infusion rate. Nonoxi-
dative glucose disposal was calculated as the difference between
glucose utilization and glucose oxidation.
Statistical analysis
Data are expressed as mean SEM. Parameters were compared
before and after LPD by one-way ANOVA for repeated measure-
ments. P values <0.05 were considered statistically significant.
Results
Renal parameters
After three months on LPD, plasma creatinine levels (455 43
vs. 448 72 jkmol liter'), isotopically determined GFR (13.6
3.1 vs. 11.6 2.1 ml mm '), and urea clearance rate (4.2 0.6
vs. 3.2 0.3 nil min ')were not significantly modified (Table 1).
Plasma urea and urinary urea dramatically declined from 25.0
3.8 to 8.3 2.4 mmol liter' (P < 0.001) and 105 17 to 27
4 i.tmol min (P < 0.001), respectively, confirming a satisfactory
compliance with the diet. Before and after LPD, urea clearance
rate increased during the euglycemic clamp, this increment reach-
ing significance only after LPD (from 4.2 0.6 to 5.6 1.3 m1
min' (P = 0.13) at the start of the study and from 3.2 0.3 to
7.7 1.8 ml min' (P < 0.05 after 3 months on LPD).
Nutritional parameters
Weight did not significantly change (Table 2). All patients
reported a general feeling of well being, and did not change their
lifestyle during the three months of the study. No significant
change was observed concerning mid-arm circumference, triceps
skinfold thickness, serum protein or albumin levels.
Metabolic parameters at postabsotptive state
Postabsorptive plasma glucose (5.0 0.1 vs. 4.7 0.1 mmol
liter'; P < 0.05) and insulin (14.0 3.7 vs. 8.1 1.5 tU m1 ';
P < 0.05) levels were lower after LPD. Protein oxidation was
lower after LPD (0.37 0.09 vs. 0.07 0.01 mg kg' min';
P < 0.01; Table 3). Nonproteic substrate oxidation rates did not
significantly differ before and after the diet, although they slightly
increased: glucose oxidation, 1.46 0.31 vs. 1.71 0.28 mg kg1
min; lipid oxidation, 0.79 0.08 vs. 1.02 0.12 mg kg'
min'). Resting energetic production rate was increased on LPD
Table 3. Substrate oxidation rates in the postabsorptive state before
and after LPD
Before After
Glucose oxidation 1.46 0.31 1.71 0.28
mg kg ' min
Lipid oxidation 0.79 0.08 1.02 0.12
mg kg mm -J
Protein oxidation 0.29 0.06 0.07 0.Ola
mg kg' min'
Energy 15.72 0.48 17.16 0.67a
production rateCal kg' min
P < 0.05
from 15.72 0.48 to 17.16 0.67 Cal kg' mm (P < 0.05);
changes in individual values are shown in Figure 2. Uric acid level
decreased under LPD from 580 33 to 380 23 .rmol liter'
(P < 0.01). Arterial pH (7.39 0.01 vs. 7.40 0.01; NS) and
bicarbonates (24.2 1.2 vs. 24.5 1.3 mmol liter'; NS) did not
change. Total calcium (2.31 0.09 vs. 2.42 0.08 mmol liter'),
phosphorus (1.44 0.21 vs. 1.35 0.09 mmol liter'), and PTH
(280 139 vs. 177 86 pg ml) varied without reaching
significance. Hemoglobin (11.5 0.7 vs. 11.1 0.5 g dl') and
hematocrit (34.0 2.1 vs. 33.4 1.5%) did not change signifi-
cantly.
Clamp study
All subjects were clamped at the same glycemic level (4.8 mmol
Iiter1) maintained constant (mean CV = 3.5%) (Table 4 and
Fig. 3). Identical insulin infusion rates resulted in lower insulin
levels after LPD (1st step, from 80.0 10.6 to 69.0 6.7 U
mL'; 2nd step, from 582 88 to 481 63 mU m1'), but the
differences did not reach significance. The glucose infusion rates
to maintain euglycemia were higher on LPD (1st step, 3.65 0.65
vs. 5.95 0.86mg kg1 min', P < 0.05; 2nd step, 7.32 0.93
vs. 9.37 0.56 mg kg' min', P < 0.05), indicating improved
insulin sensitivity. After three months of LPD, glucose oxidation
rate was more efficiently stimulated at the first step (2.36 0.29
vs. 3.37 0.35 mg kg' min'; P < 0.05). Glucose nonoxidative
disposal also increased (1st step, from 1.29 0.51 to 2.58 0.68
mg kg 'min , P < 0.05; 2nd step, from 3.74 0.74 to 5.31
0.41 mg kg ' min', P < 0.05). Energetic production rates were
higher after LPD (1st step, from 15.78 0.64 to 17.51 0.56 Cal
kg' min', P < 0.01; 2nd step, from 16.67 0.65 to 18.24
0.47, P < 0.05). LPD did not produce any change concerning the
inhibition of lipid oxidation during the clamp.
Table 1. Nephrologic parameters before and after LPD
Before After
Basal/clamp 25.0 3.8/23.8 3.9 8.3 2.4/8.0 2.2a
plasma urea
mmol iiter1
Basal/clamp
urinary urea
p.mol . min'
Basal/clamp
urea
clearance
ml mm'
P < 0.001
Table 2. Nutritional parameters before and after LPD
Before After
Body weight kg 73.5 3.8 72.0 2.8
Triceps skinfold 11.1 0.18 10.6 0.16
thickness mm
Mid-arm 308 9 301 6
circumference
Serum protein 68 3.2 69 3.0
g liter'
Serum albumin 39.9 1.8 39.7 1.9
g liter'
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Fig. 2. Individual resting enelgy production rates before and after LPD.
Table 4. Insulin-stimulated substrate oxidation rates and nonoxidative
glucose disposal before and after LPD
T
1st step
V
6'
Ca
U)o 5a.
U)
4.
0 )3.
oEC 2-
U)
Cl)00 1-
(!3
0-
Basal
5,
4,
C0
CU . 3,
E 2'
Basal
2nd step
First step Second step
Before After Before After
80.0 10.6 69 6.7 582.8 88.2 481 63.7
1st step 2nd step
Plasma insulin
p.U . flJ1
Glucose oxidation 2.36 0.29 3.37 0.35a 358 0.36 4.06 0.35
mg .kg min1
Glucose nonoxidative 1.29 0.50 258 0.68a 3.74 0.74 531 0.41
disposal
mg kg' min'
Energy production rate 15.78 0.64 17.51 0.5& 16.67 0.65 18.24 0.47a
Cal-kf' -min'
Lipid oxidation 0.46 0.10 0.60 0.09 0.30 0.10 0.27 0.10
mg - kg' . min'
a P < 0.05
bp < 0.01
Discussion
In six nondialyzed chronically uremic patients, three months on
a very low-protein diet produced significant beneficial effects on
glucose metabolism, During the postabsorptive state, plasma
glucose and insulin levels were lower, suggesting a better insulin
sensitivity, which was confirmed by the hyperinsulinemic euglyce-
mic clamp study. The use of indirect calorimetry showed that the
increase of glucose utilization could be attributed to a more
efficient stimulation of both glucose oxidation and nonoxidative
disposal, at moderate hyperinsulinemia (70 to 80 jxW m11), and
predominantly to nonoxidative glucose disposal at a pharmaco-
logical level (500 to 600 xU ml'). In the postabsorptive state
and under insulin stimulation, energy production rates were
significantly higher after LPD. It is noteworthy that during the
three month follow-up no other catabolic factor was present.
0
1 .2
1.0
C 080c
0.2
0.0
Basal 1st step 2nd step
Fig. 3. Insulin-stimulated substrate oxidation rates and nonoxidative glucose
disposal before ) and after (LII) LPD. *p < 0.05.
Consequently, the increase in EPR appeared to be related to the
change in alimentary protein intake alone.
Insulin resistance is a well-known feature of chronic uremia [1],
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and we have previously described its improvement by LPD [3].
The use of a euglycemic clamp combined with indirect calorimetry
to localize the defective pathway of glucose utilization in chroni-
cally uremic patients is logical, but requires methodological
cautiousness. First, metabolic acidosis is a common complication
of CRF, that can be ameliorated by LPD, due to the low acidifying
activity of the diet [Ii]. The correction of metabolic acidosisperse
ameliorates insulin sensitivity [121. For these reasons, metabolic
acidosis was an exclusion criterion for entering the study. Initially
close to normal levels, arterial pH and bicarbonates were not
significantly modified by three months of diet, and therefore did
not influence the results. Second, the hyperinsulinemic euglyce-
mic clamp augments urea clearance in normal subjects, leading to
erroneously elevated protein oxidation rates as calculated on the
basis of urinary N excretion [17], and an up to 5% underestima-
tion of glucose oxidation [151. Our results show that this effect is
also present in chronically uremic subjects, but more moderately
than in healthy subjects, and that it leads to nonsignificant changes
in lipid and carbohydrate oxidation rates. However, we corrected
the N urinary excretion rate as proposed by Thorburn et al [15], in
order to minimize this source of error. Third, in calculating the
nonoxidative glucose disposal rate as the difference between
exogenous glucose infusion rate to maintain euglycemia and
glucose oxidation, we neglected the potential influence of a
change in endogenous glucose production insulin sensitivity in-
duced by the diet. However, endogenous glucose production is
known to be virtually suppressed in uremic patients at the insulin
levels we used [51. Consequently, modifications it might have
undergone would not interfere in our conclusions concerning
glucose storage. Finally, it should be noted that insulin infusion
produces greater effects on glucose oxidation and storage after
LPD, in spite of lower levels of the hyperinsulinemic plateau, in
relation with the increase in insulin metabolic clearance rate as we
have previously described [4].
The improvement induced by LPD concerns both oxidative and
nonoxidative pathways in our patients, at least at the first step of
the clamp study. Comparing uremic patients to normal subjects,
Castellino showed that their defect of glucose utilization was
caused by resistance to insulin of glucose nonoxidative disposal
[5]. Our patients presented a more advanced degree of CRF,
raising the possibility that glucose oxidation may also resist
stimulation by insulin in advanced CRF. In accordance with this
hypothesis, using 13C glucose as a tracer, Kaihan et al found that
glucose oxidation is reduced in dialyzed uremic patients in the
postabsorptive state [18]. However, insulin action was not consid-
ered in their report. The improvement in glucose oxidation
sensitivity to insulin probably plays a role in the better glucose
tolerance after LPD [3], as the improvement is observed at an
insulin level that can be attained under physiological conditions.
The mechanism of the effect of LPD on insulin sensitivity is not
known. Chronically uremic patients cumulate many factors asso-
ciated with insulin resistance that may be corrected by the diet.
Metabolic acidosis is one of these factors which was not present in
our patients. A better control of secondary hyperparathyroidism,
as previously reported with LPD in a larger number of patients
[19], may interact with glucose metabolism. Diet-induced changes
in calcium, phosphorus and PTH levels did not reach significance
in this study, because of the small number of patients, but this
possible indirect effect may be important. Hyperuricemia is
associated with insulin resistance in nondiabetic and nonuremic
subjects [20], and three months of LPD significantly lowered uric
acid levels in our patients. To our knowledge, no attempt has been
made to study modifications of insulin action related to changes in
uric acid levels, but it seems probable that this is a marker, rather
than a causative factor. The decreased production of a putative
factor derived from dietary protein, and able to induce insulin
resistance remains a major hypothesis concerning the mechanism
of the effect of the diet [21]. Finally, it should be noted that the
diet does not necessarily improve insulin sensitivity by acting on a
mechanism that produces insulin resistance specifically in CRF.
LPD has been shown to improve insulin sensitivity of nonuremic
subjects, such as diabetics without renal impairment [7]. The effect
on glucose oxidation, that is not known to be resistant to insulin in
CRF, may also be nonspecific to renal failure.
The elevation of glucose oxidation is not counterbalanced by a
reciprocal reduction of lipid oxidation, and the decrease of
protein oxidation is not sufficient to equilibrate it. Protein oxida-
tion is a minor component of EPR. As calculated by Ferrannini
[16], a 50% misjudgment concerning protein oxidation leads to a
1.2% error in EPR. The energy production rate is therefore
increased by LPD in our patients. Resting energy production rate
is normal [5, 22] or may be slightly low [23] in CRF, and
malnutrition in these patients is thought to be the consequence of
inadequate caloric intake [24], that may be aggravated under LPD
if the energy supply is not sufficient [9, 25], as observed in normal
subjects [10]. Kopple et a! have shown that the maintenance of a
neutral nitrogen balance in uremic patients on moderately low-
protein diet (0.55 to 0.60 g protein• kg1 day') depends on the
energy supply [26], and they recommended an energy intake of
approximately 35 kCal kg' dayt, the quantity initially
proposed to our patients. To our knowledge, the notion that
protein-restricted diets may, in fact, raise energy production rate
has not yet been reported. This energy-expending effect may be
due to the diet itself, or to the ketoanalogs, although the
transamination reaction is not known to have a substantial
energetic cost [27, 28]. As the energy requirements of normal
individuals with moderate physical activity are reported to he
about 1.6 to 1.7 times the basal energy expenditure [29], 40 kCal
• kg1 day' is probably preferable to 35 if protein intake is
extremely restricted. Because energy requirements are subject to
sizable interindividual variations, the monitoring of body wt and
other nutritional parameters remains crucial in patients on such
diets, and regular energy production rate determinations may be
useful. However, it should be noted that no significant deteriora-
tion of nutritional parameters appeared in our patients during the
three-month survey. A transient decrease in body wt is frequently
observed during the first months on LPD, that is progressively
regained later with dietary adjustment as shown by longer (18
months) follow-up [301. In our study, patients were seen monthly
for a dietary interview.
In summary, in six patients with CRF, three months on a LPD
produced an improvement of insulin action on glucose oxidation
and nonoxidative utilization that was significant at a moderate
insulin level. Insulin-stimulated glucose oxidation may be im-
paired in CRF, at least when GFR is below 20 ml min1. The
improvement of uremic insulin resistance by a LPD may be
explained by several mechanisms: directly by lowering the produc-
tion of a uremic toxin, indirectly by a reduction in secondary
hyperparathyroidism, and nonspecifically in the same way that it
improves insulin action in nonuremic patients [7]. The beneficial
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effect of the diet was accompanied by a slight increase in energy
production rate, that can be considered as an adverse effect and
that justifies intensification of nutritional monitoring and surveys
of caloric intake. From a practical point of view, this suggests that
LPD may be helpful in states of insulin resistance other than CRF
as previously proposed [7], and confirms the importance of a
sufficient caloric intake for weight maintenance [9, 25, 26].
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Appendix
The composition of one Cetolog tablet (mg) is:
ketoisoleucine, L-ornithine: 153.24
ketovaline, L-ornithine: 72.67
ketoleucine, L-lysine: 161.78
ketovaline, L-lysine: 76.77
ketoleucine, L-histidine, H20: 50.72
DL-hydroxymethioninate Ca: 28.30
L-tyrosine: 151.54
L-threonine: 74.68
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